These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 20920997

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
    Guo Y, Shi M, Shen X, Yang C, Yang L, Zhang J.
    Clin Colorectal Cancer; 2014 Jun; 13(2):110-8. PubMed ID: 24461997
    [Abstract] [Full Text] [Related]

  • 4. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW.
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [Abstract] [Full Text] [Related]

  • 5. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
    Skof E, Rebersek M, Hlebanja Z, Ocvirk J.
    BMC Cancer; 2009 Apr 22; 9():120. PubMed ID: 19386096
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N, Heinemann V.
    Clin Colorectal Cancer; 2008 Mar 22; 7(2):110-7. PubMed ID: 18501070
    [Abstract] [Full Text] [Related]

  • 8. Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
    Li W, Xu J, Shen L, Liu T, Guo W, Zhang W, Chen Z, Zhu X, Li J.
    BMC Cancer; 2014 Dec 19; 14():986. PubMed ID: 25527007
    [Abstract] [Full Text] [Related]

  • 9. Current status of capecitabine in the treatment of colorectal cancer.
    Rothenberg ML.
    Oncology (Williston Park); 2002 Dec 19; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
    [Abstract] [Full Text] [Related]

  • 10. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J.
    J Clin Oncol; 2007 Oct 20; 25(30):4779-86. PubMed ID: 17947725
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
    Ocvirk J, Rebersek M, Boc M.
    Anticancer Res; 2011 May 20; 31(5):1777-82. PubMed ID: 21617239
    [Abstract] [Full Text] [Related]

  • 13. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
    Mazard T, Ychou M, Thezenas S, Poujol S, Pinguet F, Thirion A, Bleuse JP, Portales F, Samalin E, Assenat E.
    Cancer Chemother Pharmacol; 2012 Mar 20; 69(3):807-14. PubMed ID: 22037922
    [Abstract] [Full Text] [Related]

  • 14. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
    Köhne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Müller L, Janssens J, Bokemeyer C, Reimer P, Link H, Späth-Schwalbe E, Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E.
    Ann Oncol; 2008 May 20; 19(5):920-6. PubMed ID: 18065406
    [Abstract] [Full Text] [Related]

  • 15. Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
    Cartwright T, McCollum D, Boehm KA.
    Am J Clin Oncol; 2010 Jun 20; 33(3):307-13. PubMed ID: 20375835
    [Abstract] [Full Text] [Related]

  • 16. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
    Uygun K, Bilici A, Kaya S, Oven Ustaalioglu BB, Yildiz R, Temiz S, Seker M, Aksu G, Cabuk D, Gumus M.
    Asian Pac J Cancer Prev; 2013 Jun 20; 14(4):2283-8. PubMed ID: 23725128
    [Abstract] [Full Text] [Related]

  • 17. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec 20; 14(80):230-3. PubMed ID: 16400749
    [Abstract] [Full Text] [Related]

  • 18. XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.
    Sakar B, Gumus M, Basaran M, Argon A, Ustuner Z, Ustaoglu MA, Saglam S, Guney N, Tenekeci AN, Aykan NF.
    Oncology; 2007 Dec 20; 73(5-6):298-304. PubMed ID: 18477855
    [Abstract] [Full Text] [Related]

  • 19. Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).
    Ding HH, Wu WD, Jiang T, Cao J, Ji ZY, Jin JH, Wang JJ, Song WF, Wang LW.
    Tumour Biol; 2015 May 20; 36(5):3361-9. PubMed ID: 25534239
    [Abstract] [Full Text] [Related]

  • 20. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
    Lim SH, Kim TW, Hong YS, Han SW, Lee KH, Kang HJ, Hwang IG, Lee JY, Kim HS, Kim ST, Lee J, Park JO, Park SH, Park YS, Lim HY, Jung SH, Kang WK.
    Br J Cancer; 2015 Nov 17; 113(10):1421-6. PubMed ID: 26505681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.